Hemophagocytosis in Critically Ill Adult Patients
ConditionHemophagocytosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorUniversity of Ulm
About this trial
The purpose of the study is to find out whether non-responsiveness to therapeutic recombinant human granulocyte colony-stimulation factor (rhG-CSF) is associated with hemophagocytosis in critically ill adult patients with cytopenias.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age > 18 years
critically ill adult patients
leukopenia and thrombocytopenia
rhG-CSF therapy
Disqualifiers
life expectancy < 24 hours
inclusion in other studies
trauma patients with reanimation on scene or immediately dying on hospital admission
pregnancy
Trial population
Patients with leukopenia who are routinely treated with rhG-CSF
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
40 Participants
are grouped into 1 trial groupGroup A: patients with cytopenias
Trial outcomes
Primary outcomes
1
responsiveness to recombinant human granulocyte colony-stimulating factor (rhG-CSF)
increase in leukocytes
Time frame
within 7 daysSecondary outcomes
1
8 clinical HLH criteria
degree of fulfillment x out of 8 clinical HLH criteria
Time frame
7 daysOther outcomes
1
differential blood count, enzymes,biomarkers,immunophenotype
Differential blood count, lactate dehydrogenase, C reactive protein, fibrinogen, triglycerides, ferritin,liver enzymes, aspartate aminotransferase, soluble cluster of differentiation 25, cytokines, procalcitonin biomarkers,immunophenotype (flow cytometry)
Time frame
7 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov